Literature DB >> 2872034

Dose-dependent pharmacokinetics of zoxazolamine in the rat.

M Van der Graaff, N P Vermeulen, I E Crul, D D Breimer.   

Abstract

Zoxazolamine (ZX) is a model substrate frequently used in studies on (methylcholanthrene-inducible) hepatic cytochrome P-450 activity. The iv pharmacokinetics of ZX were studied in rats at four dose levels: 5 mg X kg-1 (n = 6), 25 mg X kg-1 (n = 6), 50 mg X kg-1 (n = 5), and 60 mg X kg-1 (n = 4). Concentrations of ZX in blood, as well as the urinary excretion of unchanged ZX and chlorzoxazone, were determined. The apparent systemic clearance (CLs,app) decreased with increasing dose from 52.6 +/- 3.9 at 5 mg X kg-1 to 9.3 +/- 0.4 ml X min-1 X kg-1 at 60 mg X kg-1. The apparent elimination half-life, t1/2,app, increased from 16.1 +/- 0.3 min to 141 +/- 28.5 min. There was only slight concentration dependency of plasma protein binding: 86.0 +/- 0.9% at 4.2 +/- 0.2 micrograms X ml-1 (n = 6) vs. 80.4 +/- 0.4% at 27.1 +/- 1.1 micrograms X ml-1 (n = 6). Since from clearance and protein binding data nonrestrictive clearance of ZX could be inferred, this small change in binding was regarded as irrelevant for the interpretation of pharmacokinetic data of ZX. The blood-plasma concentration ratio was larger than unity: 2.11 +/- 0.09 at 5.4 +/- 0.9 micrograms X ml-1, and 1.85 +/- 0.08 at 47.9 +/- 4.9 micrograms X ml-1 (n = 5).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872034

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Pharmacodynamics of zoxazolamine and chlorzoxazone in rats.

Authors:  M Yasuhara; G Levy
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

2.  Alterations in xenobiotic metabolism in the long-lived Little mice.

Authors:  Daniel Amador-Noguez; Adam Dean; Wendong Huang; Kenneth Setchell; David Moore; Gretchen Darlington
Journal:  Aging Cell       Date:  2007-05-23       Impact factor: 9.304

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.